Recombinant Human Erythropoietin in Anaemic Patients with End-Stage Renal Disease
DOI:
https://doi.org/10.51984/x0q8ha11Keywords:
Erythropoietin, Anaemia, End-stage renal disease, Haemodialysis, HaematocritAbstract
The effect of erythropoietin (EPO) on the anaemia of end-stage renal disease was investigated in 76 transfusion-dependent haemodialysis patients. EPO was administered intravenously in a dose of 50μ/kg, 3 times a week for 12 weeks. The haematocrit had risen from 18.7 ± 1-9 to 26.6 ± 3.8 on day 84. Fifty-eight patients (76.3%) responded with an increase in haematocrit of ≥6. Complications included hypertension (21.1%), iron deficiency (18.4%), thrombosis of vascular access (7.9%). This relatively low rate response could be accounted for by differences in the treatment policy. It remains to be seen whether the standard protocol of EPO use in renal failure would improve the response.
Downloads
References
Krautez S & Jacobson, L. Erythropoietin and the regulation erythropoiesis, University of Chicago Press, Chicago, 1970.
Goldberg M., Dunnig, S. & Bunntt, H. Regulation of the erythropoietin gene. Science, 1988; 242:1412.
Brown J., Cohen A. & Egrie, J. Erythropoietin, gene cloning protein structure and biologic properties. Symp. Quant Biol, 1986; 51:693.
Choen R., Clemons G. & Ebbe S. Correlation between bioassays and radio-immunoassay for erythropoietin in human serum and urine concentrates. Proc. Soc. Exp. Boil. Med. 1985; 110:29.
Whinerals C., Oliver D., & Pippard M. et al. Effect of human erythropoietin derived from recombinant DNA-on the anaemia of patients maintained by chronic haemodialysis. Lancet, 1986; 2:1175.
Eschbach J., Egrie J., Downing M. et al. Correction of the anaemia of end stage renal disease with recombinant human erythropoietin. N. Engl. J. Med. 1987; 316:37.
Eschbach J., Abdulhadi M., Browne J. et al. Recombinant human erythropoietin in anaemic patients with end stage kidney disease. Results of a phase III multicentre clinical trial. Ann. Intern. Med. 1989; 111:992.
Nielsen O. & Thaysen J. Response to erythropoietin in anaemic haemodialysis patients. J. Int. Med. 1989; 226:89.
Pattern K. G. The uses of recombinant human erythropoietin. Saudi Med. J. 1994; 15:1.
Ellsworth A., Dugdale D., Wilt D. & Oliver L. Mosby's 1997 Medical Drug Reference. Mosby. Philadelphia, 1997.
Tietz N. W. Clinical guide to laboratory tests. W. B. Saunders Company. Philadelphia, 1995.
Winearb C. Treatment of anaemia in renal failure. Prescriber's J. 1992; 32:238.
De March S. Erythropoietin in anaemia of chronic diseases. Clin. Exp. Rheumatol, 1993; 11:429.
Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. B. Med. J. 1990;300:573.
Macdougall I. Poor response to erythropoietin. B. Med. J. 1995; 310: 1424.
Ludwing H, Fitz E, Leitgeb C. et al. Prediction of response to erythropoietin treatment in chronic anaemia of cancer. Blood, 1994; 84:1056.
Stevens M, J, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. B. M. J. 1992; 306:474.
Harris DC, Chapman JR, Stewart JH, et al. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of dialysis. Austral N Z J Med, 1991; 21:693.
Zachee P. Controversies in selection of epoietin dosages: issues and answers. Drugs, 1995; 49:536.
Abraham P. A. Controversies in determination of epoietin dosages. Clin pharmacokient, 1992; 22:409.
Milman N. Stranberg PN & Visfeldt J. Serum ferritin in patients on regular peritoneal and haemodialysis treatment: relation to marrow haemosiderin iron stores. Dan Med Bull, 1984; 31:245.
Macdougall IC, Cavill I, Blum B. et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ, 1992; 304:225.
Downloads
Published
Issue
Section
License
This article is published open access under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). You may copy, redistribute, adapt and build upon it for non-commercial purposes, provided you credit the authors, cite the original publication in the Journal of Medical Sciences with its DOI, indicate any changes, and distribute any adaptations under the same licence. Copyright rests with the authors. For commercial reuse, please contact the corresponding author. Full terms: https://sebhau.edu.ly/journal/joms/copyright-licensing




















